BariatricNurseD said:Dead space is the answer to the missing dose.
I am going to disagree with reconstituting low as a general rule. More diluent, more punctures, more in-use days at room temperature, and the stability trade-off is real. Precision is not the only variable being optimised.
The figures, for anyone assembling their own picture. Red flags, in rough order of how much they should worry you: no verifiable address, no batch numbers, prices far under market, vendor-commissioned tests only, pressure toward irreversible payment, and shipping with no temperature control.
VendorMark said:I am going to disagree with reconstituting low as a general rule.
Coming at VendorMark’s question from a different direction. Prices dramatically below market are the strongest single signal, and the reason is arithmetic rather than suspicion. Synthesis, testing, and cold-chain shipping have floors. A price well under the floor means something was skipped, and the two things that get skipped are testing and content.
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesEst. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemA narrower follow-up, since the general answer is now clear:
How much material I am losing to dead space, and whether that explains why a 10mg vial gives me nine usable draws rather than ten?
OP back with an update, since a thread like this is useless without one.
Follow-up: it was dead space. Switching to a low-dead-space fixed-needle syringe gave me the tenth dose back.